



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Minoru Yoshida et al. Art Unit : 1654
 Serial No. : 10/505,380 Examiner : Thomas Sweeney Heard
 Filed : June 17, 2005 Conf. No. : 5153
 Title : HISTONE DEACETYLASE INHIBITORS AND METHODS FOR PRODUCING
 THE SAME

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

1. Supplemental Information Disclosure Statement (1 page);
2. Form PTO-1449 (2 pages);
3. Copies of Cited References (20 references); and
4. A Return Postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 7/25/06

Teresa A. Lavoie
 Teresa A. Lavoie, Ph.D.
 Reg. No. 42,782

Fish & Richardson P.C.
 60 South Sixth Street, Suite 3300
 Minneapolis, MN 55402
 (612) 335-5070 telephone
 (612) 288-9696 facsimile

60371042.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 31, 2006

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/



Attorney's Docket No.: 18115-002US1 / SEN-A0123P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Minoru Yoshida et al. Art Unit : 1654
 Serial No. : 10/505,380 Examiner : Thomas Sweeney Heard
 Filed : June 17, 2005 Conf. No. : 5153
 Title : HISTONE DEACETYLASE INHIBITORS AND METHODS FOR PRODUCING THE SAME

MAIL STOP AMENDMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

Submitted herewith are English-language Abstracts for Desig. ID Nos. AD, AF, AI, AK, and AL.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Date:

7/25/06

Respectfully submitted,

Teresa A. Lavoie, Ph.D.
 Reg. No. 42,782

Fish & Richardson P.C.
 60 South Sixth Street, Suite 3300
 Minneapolis, MN 55402
 Telephone: (612) 335-5070
 Facsimile: (612) 288-9696

60370684.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 31, 2006

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/

Sheet 1 of 2

Substitute Form PTO-1449 03/2005 Information Disclosure Statement By Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18115-002US1	Application No. 10/505,380
		Applicant Minoru Yoshida et al.		
		Filing Date June 17, 2005	Group Art Unit 1654	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,399,568	06/04/02	Nishino et al.			
	AB	2003/0078369	04/24/03	Meinke et al.			
	AC	2002/0120099	08/29/02	Nishino et al.			

Foreign Patent Documents or Published Foreign Patent Applications


Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	
	AD	11-130795	05/18/99	JP			Abst.	
	AE	WO 00/21979	04/20/00	WIPO				
	AF	WO 00/52033	09/08/00	WIPO			Abst.	
	AG	WO 01/07042	02/01/01	WIPO				
	AH	WO 03/57722	07/17/03	WIPO				
	AI	WO 03/70754	08/28/03	WIPO			Abst.	
	AJ	1 174 438	01/23/02	EPO				
	AK	2003-505417	02/12/03	JP			Abst.	
	AL	2000-256397	09/19/00	JP			Abst.	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AM	De Schepper et al., "Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin," <i>J. Pharmacol. Exp. Ther.</i> , 2003, 304(2):881-888
	AN	Finnin et al., "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors," <i>Nature</i> , 1999, 401:188-193
	AO	Furumai et al., "Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin," <i>Proc. Natl. Acad. Sci. USA</i> , 2001, 98(1):87-92
	AP	Furumai et al., "FK228 (Desipipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases," <i>Cancer Res.</i> , 2002, 62(17):4916-4921
	AQ	Jose et al., "Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α -tubulin sequence," <i>Bioorg. Med. Chem.</i> , 2004, 12:1351-1356
	AR	Kim et al., "Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase," <i>Oncogene</i> , 1999, 18:2461-2470
	AS	Komatsu et al., "Cyclic Hydroxamic-acid-containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity," <i>Cancer Res.</i> , 2001, 61(11):4459-4466

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/



FEE-Web Receipt date: 08/03/2006

10505380 - GAU: 1654

Sheet 2 of 2Substitute Form PTO-1449
(Modified 4/2001)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
18115-002US1Application No.
10/505,380**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Minoru Yoshida et al.Filing Date
June 17, 2005Group Art Unit
1654**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AT	Mori et al., "FR235222, a Fungal Metabolite, is a Novel Immunosuppressant that Inhibits Mammalian Histone Deacetylase (HDAC). I. Taxonomy, Fermentation, Isolation and Biological Activities," <i>J. Antibiot.</i> , 2003, 56(2):72-79
	AU	Nishino et al., "Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand," <i>Bioorg. Med. Chem. Lett.</i> , 2004, 14:2427-2431
	AV	Saito et al., "A synthetic inhibitor of histone deacetylase, MS-27-275, with marked <i>in vivo</i> Antitumor activity against human tumors," <i>Proc. Natl. Acad. Sci. USA</i> , 1999, 96(8):4592-4597
	AW	Yoshida et al., "Potent and Specific Inhibition of Mammalian Histone Deacetylase Both <i>in Vivo</i> and <i>in Vitro</i> by Trichostatin A," <i>J. Biol. Chem.</i> , 1990, 265(28):17174-17179

Examiner Signature

/Thomas Heard/

Date Considered

02/26/2008

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TH/